Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus THIOTHIXENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus THIOTHIXENE HYDROCHLORIDE.
HALOPERIDOL DECANOATE vs THIOTHIXENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol decanoate is a long-acting ester prodrug of haloperidol, a typical antipsychotic. Haloperidol acts primarily as a dopamine D2 receptor antagonist in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits affinity for D1, D3, D4, sigma, and 5-HT2 receptors, but its antipsychotic efficacy is primarily attributed to D2 blockade.
Thiothixene hydrochloride is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system (CNS), particularly in the mesolimbic and mesocortical pathways. It also has alpha-adrenergic blocking activity and weak anticholinergic effects.
100-200 mg intramuscular deep injection every 4 weeks. Maximum 450 mg per month.
Initial: 2-5 mg orally 3 times daily; maintenance: 15-30 mg orally per day in divided doses; maximum: 60 mg orally per day.
None Documented
None Documented
Terminal elimination half-life of haloperidol decanoate: approximately 3 weeks (range 14-28 days) due to slow release from depot and subsequent de-esterification. Steady-state achieved after 3-4 monthly doses.
Terminal elimination half-life: 34 hours (range 25–50 hrs) in adults; clinical context: allows once-daily dosing.
Renal: 40% (as metabolites; <1% unchanged); Fecal: 60% (primarily via biliary elimination).
Renal: primarily as metabolites, <1% unchanged; fecal: minor; biliary: some metabolites excreted in bile.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic